A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Trial Profile

A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs LYC 30937 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Lycera
  • Most Recent Events

    • 23 Feb 2017 Time frame of primary endpoint has changed from 6 weeks to 46 weeks.
    • 13 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 09 May 2016 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top